DVA
FY2026 Q1 · Calendar Q2 2026
DaVita Inc.
DaVita's Q1 2026 results exceeded consensus on both lines, with adjusted EPS of $2.87 versus a $2.41 estimate (a 19% surprise) and revenue of $3.42 billion versus $3.36 billion expected. The beat was driven by treatment volume running slightly ahead of forecast, helped by improving mortality trends and patient transfers from Fresenius clinic closures. Management raised full-year guidance for both adjusted operating income (to $2.15-$2.25 billion from $2.085-$2.235 billion) and EPS (to $14.10-$15.20 from $13.60-$15.00), reflecting confidence in sustained volume recovery and operational efficiency from AI and technology investments. The stock surged 23.5% on the report, well ahead of the benchmark's 1.4% move. The quarter marks a shift from the prior quarter's maintained guidance and flat volume narrative toward a more constructive trajectory, though management flagged ACA enrollment…
EPS surprise+19.1%
Market move+23.5%
